Abstract:Highlights • The crosstalk between the gut and the brain serves as a route for the spread of PD pathology in a bottom-up or top-down manner. • Gut dysbiosis is evident in PD patients and animal models and is associated with alterations in gut-derived microbial products and immune pathways promoting disease pathology. • Diet induces changes in the GM, with western diet evoking and Mediterranean diet preventing neuroinflammation and neurodegeneration associated with PD. • Gut-derived microbial products can be involved in the regulation of the immune system, the inflammation of both the intestine and the brain, and the integrity of intestinal epithelium and blood-brain barrier (BBB). • Therapeutic strategies that function by reversing gut dysbiosis and mitochondrial dysfunction may prove beneficial to treat PD pathology. Background Parkinson's disease (PD) is a disease of ⍺-synuclein aggregation-mediated dopaminergic neuronal loss in the substantia nigra pars compacta, which leads to motor and non-motor symptoms. Through the last two decades of research, there has been growing consensus that inflammation-mediated oxidative stress, mitochondrial dysfunction, and cytokine-induced toxicity are mainly involved in neuronal damage and loss associated with PD. However, it remains unclear how these mechanisms relate to sporadic PD, a more common form of PD. Both enteric and central nervous systems have been implicated in the pathogenesis of sporadic PD, thus highlighting the crosstalk between the gut and brain. Aim of Review: In this review, we summarize how the alterations in the gut microbiome can affect PD pathogenesis. We highlight various mechanisms increasing/decreasing the risk of PD development. Based on the previous supporting evidence, we suggest how early interventions could protect against PD development and how controlling specific factors, including our diet, could modify our perspective on disease mechanisms and therapeutics. We explain the strong relationship between the gut microbiota and the brain in PD subjects, by delineating the multiple mechanisms involved in neuroinflammation and oxidative stress. We conclude that the neurodetrimental effects of western diet (WD) and the neuroprotective effects of Mediterranean diets should be further explored in humans through clinical trials. Key Scientific Concepts of Review : Alterations in the gut microbiome and associated metabolites may contribute to pathogenesis in PD. In some studies, probiotics have been shown to exert anti-oxidative effects in PD via improved mitochondrial dynamics and homeostasis, thus reducing PD-related consequences. However, there is a significant unmet need for randomized clinical trials to investigate the effectiveness of microbial products, probiotic-based supplementation, and dietary intervention in reversing gut microbial dysbiosis in PD. Graphical abstract Download : Download high-res image (51KB) Download : Download full-size image

Relationship Between Short-chain Fatty Acids and Parkinson's Disease: A Review from Pathology to Clinic

Gut brain axis: an insight into microbiota role in Parkinson’s disease

Interplay of human gastrointestinal microbiota metabolites: Short-chain fatty acids and their correlation with Parkinson's disease

The role of gut-derived short-chain fatty acids in Parkinson's disease

Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease

Oral, Nasal, and Gut Microbiota in Parkinson's Disease.

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Association of Parkinson’s Disease With Microbes and Microbiological Therapy

Gut Microbiota-Induced Modulation of the Central Nervous System Function in Parkinson's Disease Through the Gut-Brain Axis and Short-Chain Fatty Acids

Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease

Research Progress of Microbiota-Gut-Brain Axis in Parkinson's Disease

The Association Between the Gut Microbiota and Parkinson's Disease, a Meta-Analysis

Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease

Gut microbiome and Parkinson's disease: Perspective on Pathogenesis and Treatment

Gut microbiota and Parkinson's disease: potential links and the role of fecal microbiota transplantation

Gut Inflammation in Association With Pathogenesis of Parkinson’s Disease

Parkinson’s Disease and Gut Microbiota

Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies

The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson's disease